LearnGlossaryMarketStocksSuperinvestorsSign in

MRVI

Maravai LifeSciences Holdings, Inc.

Healthcare · $2.1B market cap

Verdict

We can't put a fair value on MRVI right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

2 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth22.7% a year✓
Equity per share growth-24.2% a year✗
Sales growth8.2% a year✗
Free cash flow growth86.4% a year✓
Return on invested capital-8.2%✗

Follow MRVI

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

2 of the investors we track hold MRVI. In Q2 2026, 1 added. Who we track

First Eagle Investment Management

First Eagle Investment Management · as of Q2 2026

$22.9M

3,671,287 shares

First Pacific Advisors

First Pacific Advisors · as of Q2 2026

$5.5M

884,883 shares

Moves in Q2 2026

Added: First Eagle Investment Management

Insider activity

Since Sep 8, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Other filings

Brust Bernd

Chief Executive Officer · 2026-09-08

Tax withholding

$214K

About Maravai LifeSciences Holdings, Inc.

Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works